Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free PULM Stock Alerts

Pulmatrix (PULM) Competitors

Pulmatrix logo
$1.43 -0.02 (-1.38%)
As of 03:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

PULM vs. LPCN, PSTV, ADIL, CTXR, and CYCN

Should you buy Pulmatrix stock or one of its competitors? Pulmatrix's main competitors and comparable companies include Lipocine (LPCN), Plus Therapeutics (PSTV), Adial Pharmaceuticals (ADIL), Citius Pharmaceuticals (CTXR), and Cyclerion Therapeutics (CYCN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Pulmatrix compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Pulmatrix has higher revenue and earnings than Lipocine. Pulmatrix is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipocine$1.98M8.93-$9.63M-$1.79N/A
Pulmatrix$7.81M0.67-$5.16M-$1.10N/A

Pulmatrix has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Pulmatrix's return on equity.

Company Net Margins Return on Equity Return on Assets
Lipocine-755.39% -64.75% -57.62%
Pulmatrix N/A -125.65%-95.19%

In the previous week, Lipocine had 4 more articles in the media than Pulmatrix. MarketBeat recorded 6 mentions for Lipocine and 2 mentions for Pulmatrix. Lipocine's average media sentiment score of 0.89 beat Pulmatrix's score of 0.43 indicating that Lipocine is being referred to more favorably in the media.

Company Overall Sentiment
Lipocine Positive
Pulmatrix Neutral

Lipocine has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 4.7% of Lipocine shares are held by insiders. Comparatively, 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lipocine presently has a consensus target price of $15.00, suggesting a potential upside of 598.65%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Lipocine beats Pulmatrix on 9 of the 15 factors compared between the two stocks.

How does Pulmatrix compare to Plus Therapeutics?

Pulmatrix (NASDAQ:PULM) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pulmatrix has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Pulmatrix's return on equity of -125.65% beat Plus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PulmatrixN/A -125.65% -95.19%
Plus Therapeutics -230.24%-198.48%-73.13%

Plus Therapeutics has a consensus target price of $51.75, indicating a potential upside of 2,284.79%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Plus Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Pulmatrix had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for Plus Therapeutics. Pulmatrix's average media sentiment score of 0.43 beat Plus Therapeutics' score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media.

Company Overall Sentiment
Pulmatrix Neutral
Plus Therapeutics Neutral

Pulmatrix has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Pulmatrix has higher revenue and earnings than Plus Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmatrix$7.81M0.67-$5.16M-$1.10N/A
Plus TherapeuticsN/AN/A-$22.39M-$2.30N/A

Summary

Pulmatrix beats Plus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Pulmatrix compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Adial Pharmaceuticals currently has a consensus price target of $15.63, indicating a potential upside of 212.81%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adial Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Pulmatrix's return on equity of -125.65% beat Adial Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Adial PharmaceuticalsN/A -203.87% -512.41%
Pulmatrix N/A -125.65%-95.19%

In the previous week, Pulmatrix had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.89 beat Pulmatrix's score of 0.43 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Adial Pharmaceuticals Very Positive
Pulmatrix Neutral

Pulmatrix has higher revenue and earnings than Adial Pharmaceuticals. Pulmatrix is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adial PharmaceuticalsN/AN/A-$7.98M-$14.73N/A
Pulmatrix$7.81M0.67-$5.16M-$1.10N/A

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 8.0% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Adial Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

Summary

Adial Pharmaceuticals and Pulmatrix tied by winning 7 of the 14 factors compared between the two stocks.

How does Pulmatrix compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Pulmatrix has higher revenue and earnings than Citius Pharmaceuticals. Pulmatrix is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius Pharmaceuticals$7.11M2.20-$37.43M-$1.67N/A
Pulmatrix$7.81M0.67-$5.16M-$1.10N/A

Citius Pharmaceuticals' return on equity of -59.57% beat Pulmatrix's return on equity.

Company Net Margins Return on Equity Return on Assets
Citius PharmaceuticalsN/A -59.57% -34.47%
Pulmatrix N/A -125.65%-95.19%

Citius Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Pulmatrix has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Citius Pharmaceuticals and Citius Pharmaceuticals both had 2 articles in the media. Citius Pharmaceuticals' average media sentiment score of 0.94 beat Pulmatrix's score of 0.43 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Citius Pharmaceuticals Positive
Pulmatrix Neutral

Citius Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 778.73%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Citius Pharmaceuticals is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Citius Pharmaceuticals beats Pulmatrix on 10 of the 14 factors compared between the two stocks.

How does Pulmatrix compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Cyclerion Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

In the previous week, Cyclerion Therapeutics had 2 more articles in the media than Pulmatrix. MarketBeat recorded 4 mentions for Cyclerion Therapeutics and 2 mentions for Pulmatrix. Cyclerion Therapeutics' average media sentiment score of 0.58 beat Pulmatrix's score of 0.43 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Positive
Pulmatrix Neutral

Pulmatrix has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Pulmatrix's return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -87.96% -74.86%
Pulmatrix N/A -125.65%-95.19%

Cyclerion Therapeutics has higher earnings, but lower revenue than Pulmatrix. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M7.89-$3.53M-$1.66N/A
Pulmatrix$7.81M0.67-$5.16M-$1.10N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 0.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cyclerion Therapeutics beats Pulmatrix on 8 of the 13 factors compared between the two stocks.

Get Pulmatrix News Delivered to You Automatically

Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PULM vs. The Competition

Export
MetricPulmatrixPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.22M$12.45B$7.17B$14.35B
Dividend YieldN/A2.64%2.57%11.71%
P/E Ratio-1.30792.11273.4225.33
Price / Sales0.67763.43674.5098.17
Price / CashN/A14.8628.4234.96
Price / Book0.5810.3810.406.21
Net Income-$5.16M$2.83B$3.49B$358.18M
7 Day Performance2.51%-3.20%-2.06%-1.50%
1 Month Performance-6.54%0.90%-0.29%-3.52%
1 Year Performance-72.45%3.66%19.04%5.93%

Pulmatrix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PULM
Pulmatrix
0.4456 of 5 stars		$1.43
-1.4%		N/A-70.9%$5.22M$7.81MN/A20
LPCN
Lipocine
2.2475 of 5 stars		$2.25
-4.7%		$15.00
+566.7%		-25.5%$19.46M$1.57MN/A10
PSTV
Plus Therapeutics
1.432 of 5 stars		$2.70
-2.0%		$51.75
+1,816.7%		-79.2%$18.59MN/AN/A20
ADIL
Adial Pharmaceuticals
3.0816 of 5 stars		$5.93
-10.8%		$15.63
+163.5%		-42.9%$17.46MN/AN/A20
CTXR
Citius Pharmaceuticals
2.2673 of 5 stars		$0.58
-3.4%		$5.00
+762.1%		-52.6%$16.49MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PULM) was last updated on 9/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel